Brief: Sino Biopharmaceutical Says Naldemedine Approved For Marketing In Greater Bay Area
09/04/2026 11:51
April 9 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: NALDEMEDINE APPROVED FOR MARKETING IN GREATER BAY AREA FOR OPIOID-INDUCED CONSTIPATION Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit